MitoRx Therapeutics to Present New Data on MTRX31 at EASD Meeting

MitoRx Therapeutics, a biotech company based in Harwell, Oxford, is set to present groundbreaking research at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from September 28 to October 2, 2026. The company will showcase new data on its lead asset, MTRX31, a novel mitochondrial-targeted small molecule designed to restore healthy mitochondrial metabolism in high-risk obesity.

The data will highlight how MTRX31 resets the balance between fat and carbohydrate oxidation, a key mechanism that often becomes impaired in obesity. This unique mode of action differentiates MTRX31 from existing treatments and positions it as a first-in-class approach.

Jacq, in his presentation, will detail how MTRX31 has demonstrated significant reductions in body weight and fat mass in preclinical diet-induced obesity (DIO) mice models. The results show that MTRX31 not only induces weight loss but also preserves lean muscle mass, a feature that sets it apart from other weight loss interventions. The company claims that MTRX31 offers a more durable and high-quality weight loss compared to existing therapies like tirzepatide, with greater and more sustained effects.

Structural biology data will also be presented, reinforcing the company's understanding of MTRX31's molecular target. This information supports the notion that MTRX31 can effectively restore metabolic flexibility, a critical aspect of managing obesity and related metabolic disorders. The findings underscore MitoRx's commitment to developing innovative treatments for high-risk obesity, a condition affecting approximately 25-40% of the population with obesity.

MitoRx's approach focuses on reducing ectopic fat by restoring healthy mitochondrial metabolism rather than simply suppressing appetite. This strategy has the potential to deliver long-term benefits for patients, improving their overall metabolic health. The company's first-in-class small molecule, MTRX31, has already shown promising results in preclinical studies, with significant reductions in body weight and fat mass, and improvements in metabolic parameters.

The presentation at the EASD meeting will be a key milestone for MitoRx, as it aims to gain broader recognition for its innovative approach to treating obesity. The company's research could have significant implications for the treatment of obesity and related metabolic disorders, offering a new avenue for patients seeking durable and high-quality weight loss solutions.

A webcast of the presentation will be available for conference attendees through the EASD website after the event, providing a platform for further discussion and collaboration in the field of obesity research.